Lindsey Hartley is recorded as CFO at Axogen, Inc. (AXGN). The newest filing on record that lists Lindsey Hartley as CFO at Axogen, Inc. (AXGN) is dated April 29, 2026. Axogen, Inc. reported in an 8-K filed May 8, 2025 that Lindsey Hartley was appointed Chief Financial Officer (CFO), effective May 10, 2025. Axogen, Inc. reported in an 8-K filed May 8, 2025 that Lindsey Hartley was appointed Chief Financial Officer, effective May 12, 2025. The proxy statement of Axogen, Inc. reports total compensation of $1,935,226 for Lindsey Hartley in fiscal 2025, including a base salary of $395,065. Lindsey Hartley has spoken on 5 earnings calls and 2 other investor events across 1 company, most recently for Axogen, Inc. on September 10, 2026. Axogen, Inc. is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Axogen, Inc. includes Michael Dale (CEO and Board Member), Paul G. Thomas (Chairman and Board Member), Paul Thomas (Chairman) and 7 others.
“I am pleased to send you this letter informing you of your promotion to the salaried exempt position of Chief Financial Officer.”
“On May 8, 2025, Axogen, Inc. (the "Company") announced the appointment of Lindsey Hartley as its Chief Financial Officer, effective May 12, 2025 (the "Effective Date").”
“Under the terms of the agreement with BioCircuit, Oxygen will acquire 100% of BioCircuit's outstanding equity at a total price of $200 million in cash, subject to customary adjustments for cash, indebtedness, transaction expenses, and networking capital.”
“I'm pleased to report our second quarter's 2026 financial results. For the second quarter, we reported revenue of $69.7 million, reflecting growth of 23.1% year-over-year.”
“So in Q2, we expect to see an influx of more expensive product that we will be selling as a result of our transition from a tissue product to a BLA in Q4 of last year.”
“I'm pleased to report our first quarter, 2026 financial results. For the first quarter, we reported revenue of $61.5 million, reflecting growth of 26.6% compared to the first quarter of 2025.”
“We are excited about our results for the fourth quarter and the full year. Our focus on commercial execution and resource allocation have yielded top-line growth and positive cash flows.”
